Peringkat dalam Saham
#39190
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Kapitalisasi Pasar
$608.86K
Perubahan (1 hari)
-2.99%
Perubahan (1 tahun)
-36.22%
Perdagangan HVIVO plc (HVO)
Jumlah saham beredar untuk HVIVO plc (HVO)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham HVIVO plc, jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk HVIVO plc (HVO) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun |
Saham Beredar |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan |
Saham Beredar |
Perbedaan |
Negara |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
0.00 |
-
|
BE
|
